Nasdaq Notifies Lyra Therapeutics of Delisting; Company Appeals 'Public Shell' Determination

summarizeSummary

Lyra Therapeutics received a delisting notice from Nasdaq, which deemed the company a 'public shell' and cited non-compliance with listing rules, prompting the company to appeal the decision.

check_boxKey Events

• Nasdaq Issues Delisting Notice

  Lyra Therapeutics, Inc. received a Staff Determination Letter from Nasdaq on February 2, 2026, notifying the company of Nasdaq's decision to delist its common stock.

• Deemed 'Public Shell'

  Nasdaq determined the company is a 'public shell' under Listing Rule 5101, citing the suspension of its lead product candidate and the substantial reduction in force disclosed in the January 12, 2026 8-K filing.

• Failed Equity Requirement

  A separate basis for delisting was the company's failure to comply with the minimum $2,500,000 stockholders' equity requirement (Listing Rule 5550(b)), with Nasdaq denying further extensions due to the lack of current operations.

• Company Appeals Decision

  Lyra Therapeutics has requested a hearing before a Nasdaq Hearings Panel to appeal the delisting determination, which will stay the suspension of its securities pending the panel's decision.

auto_awesomeAnalysis

Lyra Therapeutics, Inc. has received a formal delisting notice from Nasdaq, citing the company's status as a 'public shell' and its failure to meet minimum stockholders' equity requirements. This follows the company's January 12, 2026 8-K, which disclosed the suspension of its lead product candidate and a significant workforce reduction, including the conversion of its CEO and CFO to consultants. Nasdaq explicitly referenced these prior disclosures as reasons for its 'public shell' determination. While the company has requested a hearing to appeal the decision, there is no guarantee of a favorable outcome, indicating a severe risk to the company's continued public listing and operational viability.